The ADDF offers funding to researchers in both nonprofit and for-profit organizations for drug discovery, clinical trials, and biomarker development. Visit our Research Priorities for specific information about our interests.
ADDF FUNDING PORTAL
The majority of funding is provided through four Core Requests for Proposals (RFPs). Letters of intent are accepted and reviewed on a rolling basis during four cycles each year, with corresponding deadlines for invited full proposals. Check back throughout the year for additional funding opportunities through our collaborations with non-profit, government, and industry partners.
CORE REQUESTS FOR PROPOSALS
Program to Accelerate Clinical Trials (PACT) RFP
Seeks to support Phase 0 through Phase 2 clinical trials, experimental medicine studies in human subjects, and IND-enabling studies.
Biomarkers Development RFP
Seeks to support the development and validation of novel and existing biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease, related dementias, and cognitive aging. Please note that peripheral biomarkers (including but not limited to modalities such as blood, saliva, urine, and ocular biomarkers) will no longer be considered through this RFP. If you are developing one of these biomarkers, please apply through the Diagnostics Accelerator: Peripheral Biomarkers RFP.
Prevention Beyond the Pipeline RFP
Seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
Drug Discovery RFP
Seeks to support programs that advance novel lead molecules to the clinical candidate selection stage, or build preclinical evidence in relevant animal models for repurposed/repositioned drugs.
OTHER REQUESTS FOR PROPOSALS
Diagnostics Accelerator: Peripheral Biomarkers RFP
Seeks to support proof-of-principle and validation studies for peripheral biomarkers and novel diagnostic technologies for Alzheimer's disease and related dementias. Funding and committed project support by from industry experts is provided through a collaboration between the ADDF, Bill Gates, and other partners.
Letter of Intent: September 14, 2018
ADDF-Harrington Scholar Program RFP
Seeks to support the preclinical development of new therapies by providing research funding and committed project support by a team of industry experts through a collaboration between the ADDF and Harrington Discovery Institute.
Accelerating Drug Discovery for Frontotemporal Degeneration RFP
Seeks to accelerate and support innovative drug discovery programs for FTD in partnership with The Association for Frontotemporal Degeneration.
OTHER ADDF FUNDING OPPORTUNITIES
Supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.
Supports scientific conferences that are relevant to our mission with grants up to $10,000. For more information, email firstname.lastname@example.org with a brief summary of your conference
Stay Updated on Upcoming Deadlines and RFP Announcements
19th International Conference on Alzheimer's Drug Discovery
September 17–18, 2018
Get more information on scholarships and early bird registration rates.